WEED, INC.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
BUDZStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001096906-26-000814
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-14.
0001096906-26-001229
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 51 previous paragraphs and 65 current paragraphs.
38 unchanged; 13 reworded; 8 added; 0 removed; 0 previous and 6 current paragraphs rearranged.
Tables are not compared: 2 previous and 3 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (8)
Current report
Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025
Current report
Results of Operations
Current report
Operating Loss; Net Loss
Current report
Revenue
Current report
General and Administrative Expenses
Current report
Professional Fees
Current report
Depreciation and Amortization
Current report
Interest Expense
Reworded paragraphs (13)
Previous wording
conjunction with WEED Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED was in the process of buying Professor Touitou’s various patents to include the bioavailability aspects of the cannabaceae plant. However, after expending over $500,000 USD to acquire the Professor Touitou’s patents, we had to terminate the agreement in 2019 due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest in working with WEED to complete the purchase of her patents and begin clinical trials upon proper funding. WEED looks to achieve that funding thru offerings of our securities.
Current wording
In conjunction with WEED Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED was in the process of buying Professor Touitou’s various patents to include the bioavailability aspects of the cannabaceae plant. However, after expending over $500,000 USD to acquire the Professor Touitou’s patents, we had to terminate the agreement in 2019 due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest in working with WEED to complete the purchase of her patents and begin clinical trials upon proper funding. WEED looks to achieve that funding thru offerings of our securities.
Previous wording
Our comprehensive net loss decreased by $265,124, from $(440,380) to $(175,256), from the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our net operating loss decreased by $270,782 from $(434,737) to $(163,955) for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Current wording
Our comprehensive net loss decreased by $2,372, from $(106,504) to $(104,132), for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Our net operating loss decreased by $3,134, from $(94,045) to $(90,911), for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Previous wording
General and administrative expenses decreased by $315,435, from $383,268 for the three months ended March 31, 2025, to $67,833 for the three months ended March 31, 2026, primarily due to decreases in our consulting services and salary.
Current wording
General and administrative expenses increased by $10,674, from $64,052 for the three months ended June 30, 2025, to $74,726 for the three months ended June 30, 2026, primarily due to increases in our consulting services and salary.
Previous wording
Our professional fees increased by $44,653 during the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our professional fees were $90,500 for the three months ended March 31, 2026, and $45,847 for the three months ended March 31, 2025. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Current wording
Our professional fees decreased by $13,622 during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Our professional fees were $10,750 for the three months ended June 30, 2026, and $24,372 for the three months ended June 30, 2025. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Previous wording
During the three months ended March 31, 2026, we had depreciation and amortization expense of $5,622, compared to $5,622 in the three months ended March 31, 2025. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Current wording
During the three months ended June 30, 2026, we had depreciation and amortization expense of $5,435, compared to $5,621 in the three months ended June 30, 2025. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Previous wording
Interest expense increased from $(5,718) for the three months ended March 31, 2025, to $(14,099) for the three months ended March 31, 2026. Our interest expense primarily relates to notes payable from related parties.
Current wording
Interest expense decreased from $(13,571) for the three months ended June 30, 2025, to $(13,221) for the three months ended June 30, 2026. Our interest expense primarily relates to notes payable from related parties.
Previous wording
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Current wording
During the six months ended June 30, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of June 30, 2026 was $1,066 and our monthly cash flow burn rate was approximately $(2,600). We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Previous wording
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Current wording
Our total assets decreased by $55,881 as of June 30, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Previous wording
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
Current wording
Our current liabilities and total liabilities increased by $194,929, as of June 30, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
Previous wording
We had cash available of $1,795 and $33,130 as of March 31, 2026 and December 31, 2025, respectively. Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $12,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Current wording
We had cash available of $1,066 and $33,130 as of June 30, 2026 and December 31, 2025, respectively. Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $2,600, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Previous wording
We had net cash used in operating activities of $57,737 for the three months ended March 31, 2026, as compared to $71,838 for the three months ended March 31, 2025. For the period in 2026, the net cash used in operating activities consisted primarily of our net loss of $(175,256), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,564, estimated fair value of shares issued for services of $26,400 and imputed interest of $2,488, respectively, and accrued expenses of $73,412. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(440,455), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,563, estimated fair value of stock based compensation and shares issued for services of $300,000 and $15,000, respectively, and further adjusted by accrued expenses of $(44,456).
Current wording
We had net cash used in operating activities of $76,466 for the six months ended June 30, 2026, as compared to $70,519 for the six months ended June 30, 2025. For the period in 2026, the net cash used in operating activities consisted primarily of our net loss of $(279,392), adjusted by depreciation and amortization of $11,057, debt discount amortization of $3,418, estimated fair value of shares issued for services of $26,400 and imputed interest of $4,976, respectively, and accrued expenses of $135,203. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(548,071), adjusted by depreciation and amortization of $11,243, debt discount amortization of $5,127, estimated fair value of stock based compensation and shares issued for services of $300,000 and $15,000, respectively, and further adjusted by accrued expenses of $(98,423).
Previous wording
For the three months ended March 31, 2026 and 2025, we had no cash flows provided from investing activities.
Current wording
For the six months ended June 30, 2026 and 2025, we had no cash flows provided from investing activities.
Previous wording
Our net cash used in financing activities for the three months ended March 31, 2026, was $(29,200), compared to $84,300 for the three months ended March 31, 2025. For the period in 2026, our financing activities related to proceeds of note payable of $30,000, offset by repayments of notes payable-related party of $(800). For the period in 2025, our financing activities related to proceeds of note payable of $45,700, offset by repayments of notes payable-related party of $(130,000).
Current wording
Our net cash used in financing activities for the six months ended June 30, 2026, was $47,200, compared to $(82,300) for the six months ended June 30, 2025. For the period in 2026, our financing activities related to proceeds of note payable of $48,000, offset by repayments of notes payable-related party of $(800). For the period in 2025, our financing activities related to proceeds of note payable of $47,000, offset by repayments of notes payable-related party of $(130,000).
Rearranged current paragraphs (6)
Current report — wording carried from elsewhere
Our comprehensive net loss decreased by $267,492, from $(546,884) to $(279,392), from the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our net operating loss decreased by $273,912 from $(528,782) to $(254,870) for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Current report — wording carried from elsewhere
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we plan to be a company focused on purchasing land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana (Cannabis) sector. Our long-term plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market, worldwide. We plan to make our brand global and therefore we will look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of any proprietary products on an international level.
Current report — wording carried from elsewhere
General and administrative expenses decreased by $304,757, from $447,320 for the six months ended June 30, 2025, to $142,563 for the six months ended June 30, 2026, primarily due to decreases in our consulting services and salary.
Current report — wording carried from elsewhere
Our professional fees increased by $31,031 during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Our professional fees were $101,250 for the six months ended June 30, 2026, and $70,219 for the six months ended June 30, 2025. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Current report — wording carried from elsewhere
During the six months ended June 30, 2026, we had depreciation and amortization expense of $11,057, compared to $11,243 in the six months ended June 30, 2025. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Current report — wording carried from elsewhere
Interest expense increased from $(19,289) for the six months ended June 30, 2025, to $(27,320) for the six months ended June 30, 2026. Our interest expense primarily relates to notes payable from related parties.